170 related articles for article (PubMed ID: 33212946)
1. The PI3K/AKT Pathway Is Activated by HGF in NT2D1 Non-Seminoma Cells and Has a Role in the Modulation of Their Malignant Behavior.
Gesualdi L; Leonetti E; Cucina A; Scicchitano BM; Sorrentino S; Tarsitano MG; Isidori A; Bizzarri M; Filippini A; Riccioli A; Cammarota M; Gigantino V; Ricci G; Catizone A
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33212946
[TBL] [Abstract][Full Text] [Related]
2. c-Src Recruitment is Involved in c-MET-Mediated Malignant Behaviour of NT2D1 Non-Seminoma Cells.
Leonetti E; Gesualdi L; Scheri KC; Dinicola S; Fattore L; Masiello MG; Cucina A; Mancini R; Bizzarri M; Ricci G; Catizone A
Int J Mol Sci; 2019 Jan; 20(2):. PubMed ID: 30646583
[No Abstract] [Full Text] [Related]
3. ERK Signaling Pathway Is Constitutively Active in NT2D1 Non-Seminoma Cells and Its Inhibition Impairs Basal and HGF-Activated Cell Proliferation.
Gesualdi L; Berardini M; Scicchitano BM; Castaldo C; Bizzarri M; Filippini A; Riccioli A; Schiraldi C; Ferranti F; Liguoro D; Mancini R; Ricci G; Catizone A
Biomedicines; 2023 Jul; 11(7):. PubMed ID: 37509533
[TBL] [Abstract][Full Text] [Related]
4. Role of c-Met/phosphatidylinositol 3-kinase (PI3k)/Akt signaling in hepatocyte growth factor (HGF)-mediated lamellipodia formation, reactive oxygen species (ROS) generation, and motility of lung endothelial cells.
Usatyuk PV; Fu P; Mohan V; Epshtein Y; Jacobson JR; Gomez-Cambronero J; Wary KK; Bindokas V; Dudek SM; Salgia R; Garcia JG; Natarajan V
J Biol Chem; 2014 May; 289(19):13476-91. PubMed ID: 24634221
[TBL] [Abstract][Full Text] [Related]
5. MiR-206 inhibits HGF-induced epithelial-mesenchymal transition and angiogenesis in non-small cell lung cancer via c-Met /PI3k/Akt/mTOR pathway.
Chen QY; Jiao DM; Wu YQ; Chen J; Wang J; Tang XL; Mou H; Hu HZ; Song J; Yan J; Wu LJ; Chen J; Wang Z
Oncotarget; 2016 Apr; 7(14):18247-61. PubMed ID: 26919096
[TBL] [Abstract][Full Text] [Related]
6. Hepatocyte growth factor (HGF) upregulates heparanase expression via the PI3K/Akt/NF-κB signaling pathway for gastric cancer metastasis.
Hao NB; Tang B; Wang GZ; Xie R; Hu CJ; Wang SM; Wu YY; Liu E; Xie X; Yang SM
Cancer Lett; 2015 May; 361(1):57-66. PubMed ID: 25727320
[TBL] [Abstract][Full Text] [Related]
7. CAF-derived HGF promotes cell proliferation and drug resistance by up-regulating the c-Met/PI3K/Akt and GRP78 signalling in ovarian cancer cells.
Deying W; Feng G; Shumei L; Hui Z; Ming L; Hongqing W
Biosci Rep; 2017 Apr; 37(2):. PubMed ID: 28258248
[TBL] [Abstract][Full Text] [Related]
8. Norcantharidin combined with EGFR-TKIs overcomes HGF-induced resistance to EGFR-TKIs in EGFR mutant lung cancer cells via inhibition of Met/PI3k/Akt pathway.
Wu H; Fan F; Liu Z; Shen C; Wang A; Lu Y
Cancer Chemother Pharmacol; 2015 Aug; 76(2):307-15. PubMed ID: 26063323
[TBL] [Abstract][Full Text] [Related]
9. PHA665752 inhibits the HGF-stimulated migration and invasion of cells by blocking PI3K/AKT pathway in uveal melanoma.
Wang Z; He C; Liu L; Ma N; Chen X; Zheng D; Qiu GH
Neoplasma; 2017; 64(3):377-388. PubMed ID: 28253717
[TBL] [Abstract][Full Text] [Related]
10. c-MET receptor as potential biomarker and target molecule for malignant testicular germ cell tumors.
Scheri KC; Leonetti E; Laino L; Gigantino V; Gesualdi L; Grammatico P; Bizzari M; Franco R; Oosterhuis JW; Stoop H; Looijenga LHJ; Ricci G; Catizone A
Oncotarget; 2018 Aug; 9(61):31842-31860. PubMed ID: 30159127
[TBL] [Abstract][Full Text] [Related]
11. Cardiotoxin III suppresses hepatocyte growth factor-stimulated migration and invasion of MDA-MB-231 cells.
Tsai PC; Chu CL; Chiu CC; Chang LS; Lin SR
Cell Biochem Funct; 2014 Aug; 32(6):485-95. PubMed ID: 24964901
[TBL] [Abstract][Full Text] [Related]
12. Matriptase is required for the active form of hepatocyte growth factor induced Met, focal adhesion kinase and protein kinase B activation on neural stem/progenitor cell motility.
Fang JD; Lee SL
Biochim Biophys Acta; 2014 Jul; 1843(7):1285-94. PubMed ID: 24685580
[TBL] [Abstract][Full Text] [Related]
13. Hepatocyte growth factor increases osteopontin expression in human osteoblasts through PI3K, Akt, c-Src, and AP-1 signaling pathway.
Chen HT; Tsou HK; Chang CH; Tang CH
PLoS One; 2012; 7(6):e38378. PubMed ID: 22675553
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of hepatocyte growth factor-mediated signaling in differentiation of pancreatic ductal epithelial cells into insulin-producing cells.
Li XY; Zhan XR; Lu C; Liu XM; Wang XC
Biochem Biophys Res Commun; 2010 Jul; 398(3):389-94. PubMed ID: 20599723
[TBL] [Abstract][Full Text] [Related]
15. Involvement of PI3K/Akt signaling pathway in hepatocyte growth factor-induced migration of uveal melanoma cells.
Ye M; Hu D; Tu L; Zhou X; Lu F; Wen B; Wu W; Lin Y; Zhou Z; Qu J
Invest Ophthalmol Vis Sci; 2008 Feb; 49(2):497-504. PubMed ID: 18234991
[TBL] [Abstract][Full Text] [Related]
16. Signaling pathway involved in cyclooxygenase-2 up-regulation by hepatocyte growth factor in endometrial cancer cells.
Yoshizawa Y; Yamada Y; Kanayama S; Shigetomi H; Kawaguchi R; Yoshida S; Nagai A; Furukawa N; Oi H; Kobayashi H
Oncol Rep; 2011 Oct; 26(4):957-64. PubMed ID: 21687953
[TBL] [Abstract][Full Text] [Related]
17. Ganglioside GM3 promotes HGF-stimulated motility of murine hepatoma cell through enhanced phosphorylation of cMet at specific tyrosine sites and PI3K/Akt-mediated migration signaling.
Li Y; Huang X; Zhong W; Zhang J; Ma K
Mol Cell Biochem; 2013 Oct; 382(1-2):83-92. PubMed ID: 23749170
[TBL] [Abstract][Full Text] [Related]
18. Differential regulation of the phosphoinositide 3-kinase and MAP kinase pathways by hepatocyte growth factor vs. insulin-like growth factor-I in myogenic cells.
Halevy O; Cantley LC
Exp Cell Res; 2004 Jul; 297(1):224-34. PubMed ID: 15194438
[TBL] [Abstract][Full Text] [Related]
19. Knockdown of SPRY4 and SPRY4-IT1 inhibits cell growth and phosphorylation of Akt in human testicular germ cell tumours.
Das MK; Furu K; Evensen HF; Haugen ØP; Haugen TB
Sci Rep; 2018 Feb; 8(1):2462. PubMed ID: 29410498
[TBL] [Abstract][Full Text] [Related]
20. PTEN reconstitution alters glioma responses to c-Met pathway inhibition.
Goodwin CR; Lal B; Ho S; Woodard CL; Zhou X; Taeger A; Xia S; Laterra J
Anticancer Drugs; 2011 Oct; 22(9):905-12. PubMed ID: 21654317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
